Oral retinoid enters trials

QLT091001 (QLT Inc), a synthetic retinoid, has begun a Phase I safety study. The orally administered compound is designed to replace 11-cis-retinal, a part of the retinoid-rhodopsin cycle that is essential for visual function, in Leber's Congenital Amaurosis (LCA) sufferers.

QLT091001 (QLT Inc.), a synthetic retinoid, has begun a Phase I safety study. The orally administered compound is designed to replace 11-cis-retinal, a part of the retinoid-rhodopsin cycle that is essential for visual function, in Leber's Congenital Amaurosis (LCA) sufferers.

There is currently no treatment for LCA, but the hypothesis of synthetic retinoid replacement therapy has been proved to be sound in earlier trials in rodent models.

The open-label, single centre study will assess the safety and tolerability of the compound when administered multiple times to healthy, adult, human volunteers. The trial will examine six separate dose strengths.

QLT hopes to announce preliminary data from the trial in the first quarter of 2009.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
© 2023 MJH Life Sciences

All rights reserved.